LONDON (Alliance News) - Technology commercialisation and investment group Imperial Innovations Group PLC Wednesday said it has completed a GBP4.25 million investment in inhaled medicines company Pulmocide Ltd.
The investment was made as part of a consortium that provided a total of GBP17 million in funding to Pulmocide.
Pulmocide, which will be based at the Imperial BioIncubator in London, is developing inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
"There is a high level of unmet medical need for respiratory syncytial virus (RSV) and invasive aspergillosis. We are confident in the team's ability to develop innovative approaches to these important healthcare challenges," Imperial Innovations said in a statement.
Imperial Innovations shares last traded at 420 pence.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright © 2013 Alliance News Limited. All Rights Reserved.
